中文 | English



Linkedbio is the newly launched services provided by Lingmed. We help companies to understand and monitor China market opportunities, define the right strategies and work with the right partners



Lingmed asset recommendation No.303

U.S. High Potential Autoimmune Disease Program seeks Chinese Partner

  • Immunomodulatory mechanism of NKT cells
  • Global & Chinese MS and SLE Epidemiology
  • Global Autoimmune Diseases Market Competition Landscape
  • Guidelines for the Treatment of MS and SLE in China
  • Lingmed innovative asset recommendation – Autoimmune Disease Program-LMP1520


Lingmed asset recommendation No.301

U.S. Allergic Rhinitis Program seeks Chinese Partner

  • Global & Chinese Epidemiology of Allergic Rhinitis
  • Global Allergic Rhinitis Drug Ranking
  • Guidelines for the Treatment of Allergic Rhinitis in China
  • Lingmed innovative asset recommendation – Allergic Rhinitis Project - LMP1526


Lingmed Newsletter July 2022

In this month summary, Lingmed recommends

  • Lingmed asset recommendation 1:Multi-indication oncology asset with innovative MoA
  • Lingmed asset recommendation 2: Necrobiosis Lipoidica from US
  • Lingmed asset recommendation 3: Allergic Rhinitis asset from US
  • Lingmed monthly webinar Aug 2022 : Gene-based medicine: viral vector-based therapeutic drugs for genetic diseases
    Berlin time:10am-11am Aug 25,2022 Register
  • The June 2022 Overview of cross-border pharmaceutical BD deals in China by Lingmed analysis team
  • The June 2022 Financial analysis of global biopharmaceuticals market by Biotechgate data analysis team


Lingmed asset recommendation No.300

US Necrobiosis Lipoidica Program seeks Chinese Partner- LMP1508

  • Global & Chinese NL Epidemiology
  • Treatment Strategy for NL in China
  • Lingmed innovative asset recommendation – Ulcerative Necrobiosis Lipoidica


Lingmed asset recommendation No.299

Innovative Mechanism of Action Oncology Program seeks Chinese Partner --LMP1590

  • Global & Chinese Breast Cancer Epidemiology
  • Global and Chinese Breast Cancer Drug Competitive Landscape
  • Overview of Chinese Breast Cancer Treatment Guidelines
  • Lingmed innovative asset recommendation – Oncology Drug with Multiple Indications - LMP1590


Lingmed Newsletter June 2022

In this month summary, Lingmed recommends

  • Lingmed asset recommendation 1:Oral antibiotics against multidrug resistance asset from US
  • Lingmed asset recommendation 2: Innovative mechanisms Immuno-Oncology asset from EU
  • Lingmed monthly webinar July : Spotlight of R&D breakthrough on woman healthcare therapeutic area Berlin time:10am-11am Tuesday,Jul 26th,2022 Register
  • The May 2022 Overview of cross-border pharmaceutical BD deals in China by Lingmed analysis team
  • The May 2022 Financial analysis of global biopharmaceuticals market by Biotechgate data analysis team




If you are interested in Lingmed historical achieved reports, please click here





Confirm your details on form below to download this report

Company name *
Your name *
Email *
Phone *
Notes

©Copyright 2013 - 2022 Lingmed Limited